

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box (430 Alexandra, Virginia 22313-1450 www.opto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,491	09/05/2003	Dagmar Beyerlein	5618.P3653	8370	
7590 04/01/2009 James C. Scheller			EXAM	EXAMINER	
BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP			WITCZAK, CATHERINE		
Seventh Floor 12400 Wilshir			ART UNIT	PAPER NUMBER	
Los Angeles, 0	Los Angeles, CA 90025		3767		
			MAIL DATE	DELIVERY MODE	
			04/01/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) BEYERLEIN, DAGMAR 10/656,491 Office Action Summary Examiner Art Unit CATHERINE N. WITCZAK 3767 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 3 (76 H; 136)a. In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO print of reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply well by statute, cause the application to become ARANDONED (38 U.S.C. § 133). An veolar received by the Office last than three months after the mailing date of this communication, even if timely filed, may reduce any	
earned patent term adjustment. See 37 CFR 1.704(b).	
Status	
1) Responsive to communication(s) filed on 11 December 2008.	
2a)☑ This action is FINAL . 2b)☐ This action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is	
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.	
Disposition of Claims	
4) Claim(s) 1-12 and 21-24 is/are pending in the application.	
4a) Of the above claim(s) is/are withdrawn from consideration.	
5) Claim(s) is/are allowed.	
6)⊠ Claim(s) <u>1-12 and 21-24</u> is/are rejected.	
7) Claim(s) is/are objected to.	
8) Claim(s) are subject to restriction and/or election requirement.	
Application Papers	
9) The specification is objected to by the Examiner.	
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.	
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119	
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).	
a) All b) Some * c) None of:	
 Certified copies of the priority documents have been received. 	
Certified copies of the priority documents have been received in Application No	
3. Copies of the certified copies of the priority documents have been received in this National Stage	
application from the International Bureau (PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list of the certified copies not received.	

Attachment(s)		
Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)	
Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date	
3) X Information Disclosure Statement(s) (PTO/G6/08)	5). Notice of Informal Patent Application.	
Paper No(s)/Mail Date 3/11/2009.	6) Other:	

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- Claims 1, 2, 3, 6, and 8 rejected under 35 U.S.C. 102(b) as being anticipated by Sicurelli et al (US 6,162,202).

Sicurelli et al disclose in Figure 4 a system comprising a needle with a first and second opening (17c), and a fluid pressure sensor (550) configured to measure a first, second, and third pressure change as therapeutic agent is injected.

 Claims 1, 2, 3, 6, and 8 rejected under 35 U.S.C. 102(b) as being anticipated by Galindo (US 4.411,657).

Galindo discloses in Figure 1 a system comprising a needle with a first and second opening (18), and a fluid pressure sensor (column 2, lines 40-50) configured to measure a first, second, and third pressure change as therapeutic agent is injected.

Application/Control Number: 10/656,491

Art Unit: 3767

 Claims 1, 2, 3, 6, and 8 rejected under 35 U.S.C. 102(e) as being anticipated by Flaherty et al (US 6.283.951).

Flaherty et al disclose in Figure 5c a system comprising a needle (62) with a first and second openings (75), and a fluid pressure sensor (column 17, lines 42-52) configured to measure a first, second, and third pressure change as therapeutic agent is injected.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- Claims 5, 7, 9, and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sicurelli et al OR Galindo OR Flaherty et al in view of Sicurelli et al OR Galindo OR Flaherty et al.

Sicurelli et al OR Galindo OR Flaherty et al discloses the claimed invention except for expressly sidelosing the size of the aperture, distance of the aperture from the end of the needle, and outer/inner diameter of the syringe. At the time the invention was made, it would have been an obvious matter of design choice to a person of ordinary skill in the art to change the are, distance, and diameters because Applicant has not disclosed that these values provide an advantage, is used for a particular purpose, or solves a stated problem. One of ordinary skill in the art would have been able to change these values in order to control the amount of flow and location of outflow as desired. Therefore, it would have been an obvious matter of design choice to modify Sicurelli et al OR Galindo OR Flaherty et al to obtain the invention as specified in claims 5, 7, 9, and 10.

Claims 11, 12, and 21-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sicurelli
et al OR Galindo OR Flahertv et al as modified by Sakariassen (US 5.662.107).

Sicurelli et al OR Galindo OR Flaherty et al disclose the claimed invention except for a computer processor coupled to the assembly. Sakariassen discloses in Figure 1 that it is known to use a computer processor coupled to a fluid pressure assembly. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of Sicurelli et al OR Galindo OR Flaherty et al with a computer processor as taught by Sakariassen, since such a modification would provide more accurate, more sophisticated, easier to display feedback than a manual pressure indicator.

Response to Arguments

Applicant's arguments filed 12/11/2008 have been fully considered but they are not persuasive.
Applicant argues that the prior art (Sicurelli, Galindo and Flaherty) does not disclose a measurement
assembly configured to measure a third pressure that is a second pressure change when the needle
penetrates tissue and the aperture of a second opening becomes occluded. Examiner disagrees. Each of
the prior art references disclose a needle with multiple apertures and a pressure sensing device. Even
though the prior art may not explicitly disclose using the device to measure a third pressure that is a
second pressure change when the needle penetrates tissues and the aperture of the second opening
becomes occluded, since each of the references discloses the needle structure claimed and a pressure
measuring assembly connected to the needle, it would be inherent that the devices could be employed in
various situations to determine pressure changes, including situations such as ones in which the pressure
changes resulting from an aperture becoming occluded.

Conclusion

Application/Control Number: 10/656,491

Art Unit: 3767

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE N. WITCZAK whose telephone number is (571)272-7179. The examiner can normally be reached on Monday through Friday, 8-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 3767

/Catherine N Witczak/ Examiner, Art Unit 3767 /Kevin C. Sirmons/ Supervisory Patent Examiner, Art Unit 3767